Drs. Fatemeh Ardeshir-Larijani and Mohamed Abazeed discuss a validated AI model that can predict how patients with advanced ...

Panelists discuss how comprehensive patient education about expected adverse effects, combined with prophylactic measures ...

The FDA has granted accelerated approval to Datroway for adults with previously-treated, locally advanced or metastatic EGFR-mutated NSCLC.

During June, investigators reported new data that has advanced the treatment landscape for lung cancer, including new FDA ...

Panelists discuss how both amivantamab plus lazertinib and osimertinib-based regimens show good central nervous system (CNS) ...

Patients on baseline steroids had lower ORR, and markedly shorter PFS survival and OS compared with those not receiving ...

In a primary efficacy population of 85 patients, the confirmed overall response rate was 46%.

A new research paper was published in Volume 16 of Oncotarget on June 17, 2025, titled "Molecular landscape of HER2-mutated ...

Recent oncology breakthroughs showcase innovative treatments and approvals, enhancing patient outcomes in CLL, RCC, NSCLC, ...

The global non-small cell lung carcinoma market is poised for significant expansion over the next decade, according to new industry projections. Valued at USD 8.25 billion in 2023, the NSCLC market is ...

Oral presentations also will highlight initial results from the TUXEDO-3 phase 2 trial (# 2005) evaluating patritumab deruxtecan in patients with metastatic breast cancer or advanced NSCLC and ...

Ivonescimab in Combination with Chemotherapy Demonstrates Statistically Significant and Strongly Positive Results in First-Line Treatment of Squamous Non-Small Cell Lung Cancer (sq-NSCLC) vs ...